J&J-Sail and AbbVie-Kestrel put a spotlight on the option-to-acquire structure — rare even in a record M&A year — with biotech and pharma leaders weighing its risk-sharing appeal against its wrinkles.
Two recent deals are focusing attention on a relatively rare structure for biotech buyouts: the option-to-acquire.
Drug developers are on pace to have one of …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Megadeals are largely missing in an otherwise healthy M&A environment for biopharma.
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might…
The prospect of patents expiring on lucrative drugs is prompting drugmakers to hunt for the next blockbuster medicines.
Pharmaceutical companies are hungry to make deals, and they’re making more than they have in years.
Biotech is dominating the (very) early 2026 deals market.
